Effect of lipopenic and hypotensive treatment on homocysteine levels in type 2 diabetics

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 327-332

  El Oudi, Mabrouka ^a   Aouni, Zied ^a   Ouertani, Haroun ^a   Mazigh, Chakib ^a   Machghoul, Salem ^a  

^a MILITARY HOSPITAL OF TUNIS   (Tunisia)

Author keywords

Complications; Homocysteine; Hypolipemiant drug; Hypotensive drug; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FOLIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; MIDDLE AGED; RISK; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; VITAMIN B 12;

EID: 77955885453     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s8240     Document Type: Review

References (34)

1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study. BMJ. 2000;321(7258): 405-412.
2. Simon DI, Fless GM, Scanu AM, Loscalzo J. Tissue type plasminogen-activator binds to and is inhibited by surface-bound Lp (a) and LDL. Biochemistry. 1991;30:6671-6677.
3. Cattaneo M. Hyperhomocystéinémie et thrombose. J Dade Behring. 2003;6-14.
4. Klee GG. Cobalamin and folate evaluation measurement of methylmalonic acid and homocysteine vs vitamin B12 and folate. Clin Chem. 2000;46:1277-1283.
5. Colombier A, DufloLeray A, Basuyau J P. Evaluation analytique du dosage de la vitamine B12 et des folates sur IMMULITE 2000. Immuno-analyse et Biologie Spécialisée. 2002;1:40-47.
6. Robinson K, Mayer EL, Miller D P, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Circulation. 1995;92:2825-2830.
7. Medina MA, Amores-Sanchez MI. Homocysteine: an emergent cardiovascular risk factor? Eur J Clin Invest. 2000;30:754-762.
8. Sadeghian S, Fallahi F, Slarifar M, et al. Homocysteine, vitamin B12 and folates levels in premature coronary artery disease. BMC Cardiovasc Disord. 2006;6:38.
9. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997;277:1775-1787.
10. Robinson K, Mayer EL, Miller D P, et al. Hyperhomocysteinemia and low pyridoxal phosphate: common and independant reversible risk factors for coronary artery disease. Circulation. 1995;92: 2825-2830.
11. Chico A, Perez A, Cordoba A, et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia. 1998;41:684-693.
12. Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med. 2004;140:94-100.
13. Hoogeveen EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia increases risk of death especially in type 2 diabetes. Circulation. 2000;101:1506-1510.
14. Hoogeveen EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol. 1998;18:133-138.
15. Aouni Z, Oudi M, Mazigh C, et al. Homocysteinaemia and degenerative complications in non insulin dependent diabetes mellitus. Tunis Med. 2005;83:537-540.
16. Buysschaert M, Dramais AS, Wallemacq PE, Hermans M P. Hyperhomocysteinemia in type 2 diabetes: relationship to mac-roangiopathy nephropathy and insulin resistance. Diabetes Care. 2000;12:1816-1822.
17. Otmane A, Makrelouf M, Bouchama Rim, Boucelma M, Berrah A, Zenati A. Dosage de l'homocystéine totale dans une cohorte de diabétiques de type 2. Revue Francophone des Laboratories. 2007; N396.
18. Sahin M, Tutuncu NB, Ertugrul D, Tanaci N, Guvener ND. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. J Diabetes Complications. 2007;21:118-123.
19. Derosa G, Franzetti I, Chwatko G, Bald E. Total plasma homocysteine levels in type 2 diabetes patients. Diabetes Nutr Metab. 2000;13: 312-324.
20. Hoogeven EK, Kostense PJ, Jacobs C, Bouter LM, Hein RJ, Stehouwer CDA. Does metformin increase the serum total homocysteine level in non insulin dependant diabetes mellitus? J Intern Med. 1997;242:389-394.
21. Mooradian AD, Failla M, Hoohwerf B, Maryniuk M, Wylie-Rosett J. Selected vitamins and minerals in diabetes. Diabetes Care. 1994;17:464-479.
22. Araki A, Sako Y, Ito H. Plasma homocysteine concentrations in Japanese patients with non insulin dependant diabetes mellitus: effect of parenteral methylcobalamin treatment. Atherosclerosis. 1993;103:149-157.
23. Rudy A, Kowalska I, Straczkowski M, Kinalska I. Homocysteine concentrations and vascular complications in patients with type 2 diabetes. Diabetes Metab. 2005;31:112-117.
24. Fonseca VA, Mudaliar S, Schmidt B, Fink LM, Kern PA, Henry RR. Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects. Metabolism. 1998;47:686-689.
25. Bissonette R, Treacy E, Rozen R, Boucher B, Cohn JS, Geneset J. Fenofbrate raises plasma Hcy levels in the fasted and fed states. Atherosclerosis. 2001;155:455-462.
26. Vergès B. FIELD deux ans après: quelle place pour les fibrates dans le diabète de type 2? Médecine des Maladies Métaboliques. 2008;2:32-37.
27. Mayer O Jr, Simon J, Holubec L, Pikner R, Trefil L. Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates. Physiol Res. 2006;55:475-481.
28. Miltiadous G, Papakostas J, Chasiotis G, Seferiadis K, Elisaf M. Statins and homocysteine. Atherosclerosis. 2003;166:199-200.
29. Lin C P, Chen YH, Lin WT, et al. Direct effect of statins on homocysteine-induced endothelial adhesiveness: potential impact to human atherosclerosis. Eur J Clin Invest. 2008;38:106-116.
30. Kaya C, Cengiz SD, Berker B, Demirtas S, Cesur M, Erdogan G. Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. 2008;92(2):635-642.
31. Clarke R, Collins R. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk. 1998;5:249-255.
32. Angeles G, Katherine Z. Homocysteine and cognitive function in elderly people. CMAJ. 2004;171:897-904.
33. Ntaios GC, Savopoulos CG, Chatzinikolaou AC, Kaiafa GD, Hatzitolios A. Vitamins and stroke:the homocysteine hypothesis still in doubt. Neurologist. 2008;14:2-4.
34. Bazzano LA. Folic acid supplementation and cardiovascular disease: the state of the art. Am J Med Sci. 2009;338:48-49.